Immuron (NASDAQ:IMRN) Sees Significant Drop in Short Interest

Immuron (NASDAQ:IMRN – Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 26,156 shares, a decrease of 60.6% from the October 15th total of 66,371 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily volume of 15,900 shares, the short-interest ratio is currently 1.6 days.

Immuron Stock Up 2.8%

IMRN traded up $0.02 on Monday, hitting $0.90. The company had a trading volume of 23,750 shares, compared to its average volume of 17,799. The company’s fifty day moving average price is $1.09 and its 200 day moving average price is $1.01. Immuron has a 1-year low of $0.68 and a 1-year high of $1.99.

Immuron (NASDAQ:IMRN – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter. The business had revenue of $1.27 million during the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Immuron in a research report on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Immuron has a consensus rating of “Sell”.

View Our Latest Report on Immuron

About Immuron

(Get Free Report)

Immuron Limited is an Australian biopharmaceutical company that develops and commercializes oral antibody-based products. Its approach uses targeted antibodies intended to bind pathogens or other biological targets in the gastrointestinal tract. The company’s principal commercial product is Travelan, an oral product designed to help prevent travelers’ diarrhea. Immuron also develops investigational therapies for infectious and inflammatory conditions, including candidates focused on Clostridioides difficile infection and other gastrointestinal diseases.

Further Reading

Receive News & Ratings for Immuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron and related companies with MarketBeat.com's FREE daily email newsletter.